International Textbook of Diabetes Mellitus, 4th Ed., Chapter 23 - The insulin resistance syndrome

References

1. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology 1979;237:E214–223.
2. Sattar N, Wannamethee SG, Forouhi NG: Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia 2008;51:926–940.
3. Huang-Doran I, Sleigh A, Rochford JJ, et al.: Lipodystrophy: metabolic insights from a rare disorder. Journal of Endocrinology 2010;207:245–255.
4. Cleland SJ, Sattar N: Impact of ethnicity on metabolic disturbance, vascular dysfunction and atherothrombotic cardiovascular disease. Diabetes, Obesity and Metabolism 2005;7:463–470.
5. Stefan N, Kantartzis K, Machann J, et al.: Identification and characterization of metabolically benign obesity in humans. Archives of Internal Medicine 2008;168:1609–1616.
6. Sattar N, Petrie JR, Jaap AJ: The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 1998;138:229–235.
7. Freeman DJ, Norrie J, Caslake MJ, et al.: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596–1600.
8. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, et al.: Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307:2499–2506.
9. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, et al.: Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993–2000.
10. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS,Ricketts SL, et al.: Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634–1639
11. Taylor R: Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008;51:1781–1789.
12. Preiss D, Sattar N: Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clinical Science (London) 2008;115:141–150.
13. Bonnet F, Ducluzeau PH, Gastaldelli A, et al.: Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. Diabetes 2011;60:1660–1667.
14. Peter A, Kantartzis K, Machann J, et al.: Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes 2010;59:3167–3173.
15. Kim CH, Kim HK, Bae SJ, et al.: Association of elevated serum ferritin concentration with insulin resistance and impaired glucose metabolism in Korean men and women. Metabolism 2011;60:414–420.
16. Succurro E, Andreozzi F,Marini MA, et al.: Low plasma insulin-like growth factor-1 levels are associated with reduced insulin sensitivity and increased insulin secretion in nondiabetic subjects. Nutrition, Metabolism and Cardiovascular Diseases 2009;19:713–719.

17. Meigs JB, O'Donnell CJ, Tofler GH, et al.: Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 2006;55:530–537.
18. Wallace AM, Sattar N: The changing role of the clinical laboratory in the investigation of polycystic ovarian syndrome. The Clinical Biochemist Reviews 2007;28:79–92.
19. Perry JR, Weedon MN, Langenberg C, et al.: Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Human Molecular Genetics 2010;19:535–544.
20. Pal D, Dasgupta S, Kundu R, et al.: Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nature Medicine 2012;18(8):1279–1285.
21. Sattar N: Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities. Diabetic Medicine 2012;29:5–13.
22. Wannamethee SG, Lowe GD, Rumley A, et al.: Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007a;30:1200–1205.
23. Wannamethee SG, Whincup PH, Lennon L, Sattar N: Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Archives of Internal Medicine 2007b;167:1510–1517.
24. Yaghootkar H, Lamina C, Scott RA, et al.: Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 2013;62:3589–3598.
25. Cook JR, Semple RK: Hypoadiponectinemia—cause or consequence of human "insulin resistance"? Journal of Clinical Endocrinology & Metabolism 2010;95:1544–1554.
26. Interleukin-6 Receptor Mendelian Randomisation Analysis Collaboration, Hingorani AD, Casas JP: The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 2012;379:1214–1224.
27. Huang J, Sabater-Lleal M, Asselbergs FW, et al.: Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood 2012;120:4873–4881.
28. Mykkanen L, Zaccaro DJ, Wagenknecht LE, et al.: Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998;47:793–800.
29. Pfister R, Sharp S, Luben R, et al.: Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Medicine 2011;8:e1001112.
30. Welsh P, McMurray JJ: B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway? Diabetologia 2012;55: 1240–1243.
31. Kozakova M,Natali A,Dekker J, et al.: Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. Arteriosclerosis,Thrombosis, and Vascular Biology 2013;33:1409–1417.
32. Sarwar N, Sattar N, Gudnason V, Danesh J: Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. European Heart Journal 2007;28:2491–2497.
33. 33 Reaven GM: Banting lecture 1988.Role of insulin resistance inhuman disease. Diabetes 1988;37:1595–1607.

34. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421.
35. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome—a new worldwide definition. Lancet 2005;366:1059–1062.
36. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of aWHO consultation. Diabetic Medicine 1998;15:539–553.
37. Alberti KG, Eckel RH, Grundy SM, et al.: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association;World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–1645.
38. Simmons RK, Alberti KG, Gale EA, et al.:The metabolic syndrome: useful concept or clinical tool? Report of aWHO Expert Consultation. Diabetologia 2010;53:600–605.
39. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–2752.
40. Gale EA: Should we dump the metabolic syndrome? Yes. BMJ 2008;336:640.
41. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005;48:1684–1699.
42. Preiss D, Sattar N: Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence. Heart 2007;93:1493–1496.
43. 43 Ferrannini E:Metabolic syndrome: a solution in search of a problem. Journal of Clinical Endocrinology and Metabolism 2007;92:396–398.
44. FordES: Rarer than a blue moon: the use of a diagnostic code for the metabolic syndrome in the U.S. Diabetes Care 2005;28:1808–1809.
45. Gale EA: The myth of the metabolic syndrome. Diabetologia 2005;48:1679–1683.
46. Hippisley-Cox J, Coupland C, Vinogradova Y, et al.: Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136.
47. Woodward M, Brindle P, Tunstall-Pedoe H: Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007;93:172–176.
48. Gami AS, Witt BJ, Howard DE, et al.: Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. Journal of the American College of Cardiology 2007;49:403–414.
49. Sattar N, Gaw A, Scherbakova O, et al.: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414–419.
50. Sundstrom J, Riserus U, Byberg L, et al.: Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006;332:878–882.

51. McNeill AM, Rosamond WD, Girman CJ, et al.: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385–390.
52. Stern MP, Williams K, Gonzalez-Villalpando C, et al.: Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676–2681.
53. Wannamethee SG, Shaper AG, Lennon L, Morris RW: Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Archives of Internal Medicine 2005;165:2644–2650.
54. Deedwania P, Barter P, Carmena R, et al.: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368:919–928.
55. Lawlor DA, Smith GD, EbrahimS:Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health Study. Diabetologia 2006;49:41–48.
56. Wang J, Ruotsalainen S,Moilanen L, et al.: The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. European Heart Journal 2007;28: 857–864.
57. Cameron AJ, Magliano DJ, Zimmet PZ, et al.: The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. Journal of Internal Medicine 2008;264:177–186.
58. Sarwar N, Gao P, Seshasai SR, et al.: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375: 2215–2222.
59. Preiss D, Welsh P, Murray HM, et al.: Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. European Heart Journal 2010;31:1230–1236.
60. Widjaja A, Morris RJ, Levy JC, et al.: Within- and between-subject variation in commonly measured anthropometric and biochemical variables. Clinical Chemistry 1999;45:561–566.
61. Gillies CL, Abrams KR, Lambert PC, et al.: Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007;334:299.
62. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002;346:393–403.
63. Carlsson LM, Peltonen M, Ahlin S, et al.: Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. New England Journal of Medicine 2012;367:695–704.
64. Fraser A, Harris R, Sattar N, et al.: Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009;32:741–750.
65. Selva DM, Hogeveen KN, Innis SM, Hammond GL: Monosaccharide- induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. Journal of Clinical Investigation 2007;117:3979–3987.
66. Yakar S, Setser J, ZhaoH, et al.: Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. Journal of Clinical Investigation 2004;113:96–105.

67. Festa A, D'Agostino R, Jr, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42–47.
68. Brunner EJ, Kivimaki M, Witte DR, et al.: Inflammation, insulin resistance, and diabetes—Mendelian randomization using CRP haplotypes points upstream. PLoS Medicine 2008;5:e155.
69. Jensen MK, Bartz TM, Mukamal KJ, et al.: Fetuin-A, type 2 diabetes, and risk of cardiovascular disease in older adults: The Cardiovascular Health Study. Diabetes Care 2012;36(5):1222–1228.
70. Tschritter O, Fritsche A, Thamer C, et al.: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003;52:239–243.
71. Martinez Cantarin MP, Keith SW, Deloach S, et al.: Relationship of adipokines with insulin sensitivity in African Americans. American Journal of the Medical Sciences 2011;342:192–197.
72. Song A, Xu M, Bi Y, et al.: Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. PLoS One. 2011;6:e19228.
73. Donahue RP, Prineas RJ, Donahue RD, et al.: Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. Diabetes Care 1999; 22:1092–1096.
74. Schultz O, Oberhauser F, Saech J, et al.: Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE 2010;5:e14328.
75. Ma LJ, Mao SL, Taylor KL, et al.: Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004;53:336–346.
76. Lijnen HR, Alessi MC, Frederix L, et al.: Tiplaxtinin impairs nutritionally induced obesity in mice. Thrombosis and Haemostasis 2006;96:731–737.
77. Mennen LI, Balkau B, Charles MA, et al.: Gender differences in the relation between fibrinogen, tissue-type plasminogen activator antigen and markers of insulin resistance: effects of smoking. D.E.S.I.R. Study Group. Data from an Epidemiological Study on Insulin Resistance Syndrome.Thrombosis and Haemostasis 1999;82:1106–1111.
78. Bonora E, Kiechl S,Willeit J, et al.: Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care 2007;30:318–324.
79. Ponthieux A, Herbeth B, Droesch S, et al.: Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis 2004;172:299–308.
80. Wannamethee SG, Sattar N, Rumley A, et al.: Tissue plasminogen activator, vonWillebrand factor, and risk of type 2 diabetes in older men. Diabetes Care 2008;31:995–1000.
81. Beydoun MA, Canas JA, Beydoun HA, et al.: Serum antioxidant concentrations and metabolic syndrome are associated among U.S. adolescents in recent national surveys. Journal of Nutrition 2012;142:1693–1704.
82. Chen H, Karne RJ, Hall G, et al.: High-dose oral vitamin C partially replenishes vitamin C levels in patients with Type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. American Journal of Physiology - Heart and Circulatory Physiology 2006;290:H137–145.
83. Grimnes G, Figenschau Y, Almas B, Jorde R: Vitamin D, insulin secretion, sensitivity, and lipids: results from a case–control study and a randomized

controlled trial using hyperglycemic clamp technique. Diabetes 2011;60:2748–2757.
84. George PS, Pearson ER, Witham MD: Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabetic Medicine 2012;29:e142–150.
85. Khan AM, Cheng S, Magnusson M, et al.: Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. Journal of Clinical Endocrinology & Metabolism 2011;96:3242–3249.